Date Filed | Type | Description |
10/13/2023 |
8-K
| Quarterly results |
10/13/2023 |
8-K
| Quarterly results |
08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
07/24/2023 |
8-K
| Quarterly results |
07/20/2023 |
8-K
| Quarterly results |
07/14/2023 |
8-K
| Quarterly results |
06/29/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
06/12/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
06/09/2023 |
4
| Amin Naseem (Director) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 47,578 shares
@ $0 |
|
06/09/2023 |
4
| Fernandes Peter (See Remarks) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 100,000 options to buy
@ $0.8264, valued at
$82.6k
|
|
06/09/2023 |
4
| Shah Parag Suresh (VP of Business Operations) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 50,000 options to buy
@ $0.8264, valued at
$41.3k
|
|
06/09/2023 |
4
| Dekker Martin (See Remarks) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 50,000 options to buy
@ $0.8264, valued at
$41.3k
|
|
06/09/2023 |
4
| Bruder Scott P (Director) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 14,607 options to buy
@ $0.8264, valued at
$12.1k
|
|
06/09/2023 |
4
| Kim Bobae (VP Reg. Affairs & Quality) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 50,000 options to buy
@ $0.8264, valued at
$41.3k
|
|
06/09/2023 |
4
| Wang Theodore T (Director) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 14,607 options to buy
@ $0.8264, valued at
$12.1k
|
|
06/09/2023 |
4
| Cloyd Mary Ann (Director) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 14,607 options to buy
@ $0.8264, valued at
$12.1k
|
|
06/09/2023 |
4
| Teufel Crispin (Director) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Granted 14,607 options to buy
@ $0.8264, valued at
$12.1k
|
|
06/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/09/2023 |
SC 13G/A
| JANUS HENDERSON GROUP PLC reports a 0% stake in Bellerophon Therapeutics, Inc. |
06/07/2023 |
SC 13D/A
| Puissance Life Science Opportunities Fund VI reports a 10.9% stake in Bellerophon Therapeutics, Inc. |
06/07/2023 |
4
| Puissance Life Science Opportunities Fund VI (10% Owner) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Sold 134,421 shares
@ $0.83, valued at
$111.6k
|
|
06/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/07/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
06/02/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
05/31/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
05/26/2023 |
SC 13G/A
| JANUS HENDERSON GROUP PLC reports a 12.1% stake in Bellerophon Therapeutics, Inc. |
05/25/2023 |
SC 13G
| JANUS HENDERSON GROUP PLC reports a 5.1% stake in Bellerophon Therapeutics, Inc. |
05/22/2023 |
4
| Kim Bobae (VP Reg. Affairs & Quality) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Sold 9,455 shares
@ $10, valued at
$94.6k
Exercised 266 options to buy
@ $7.35, valued at
$2k
Exercised 1,022 options to buy
@ $7.5, valued at
$7.7k
|
|
05/19/2023 |
4
| Puissance Life Science Opportunities Fund VI (10% Owner) has filed a Form 4 on Bellerophon Therapeutics, Inc.
Txns:
| Sold 560,000 shares
@ $9.46, valued at
$5.3M
|
|
05/18/2023 |
144
| Form 144 - Report of proposed sale of securities: |
05/15/2023 |
8-K
| Quarterly results |
05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|